Your browser doesn't support javascript.
loading
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Venugopal, Sangeetha; DiNardo, Courtney D; Loghavi, Sanam; Qiao, Wei; Ravandi, Farhad; Konopleva, Marina; Kadia, Tapan; Bhalla, Kapil; Jabbour, Elias; Issa, Ghayas C; Macaron, Walid; Daver, Naval; Borthakur, Gautam; Montalban-Bravo, Guillermo; Yilmaz, Musa; Patel, Keyur P; Kanagal-Shamanna, Rashmi; Chien, Kelly; Maiti, Abhishek; Kantarjian, Hagop; Short, Nicholas J.
Afiliación
  • Venugopal S; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • DiNardo CD; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Loghavi S; Departments of Hematopathology, and, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Qiao W; Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ravandi F; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Konopleva M; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kadia T; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Bhalla K; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jabbour E; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Issa GC; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Macaron W; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Daver N; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Borthakur G; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Montalban-Bravo G; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yilmaz M; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Patel KP; Departments of Hematopathology, and, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kanagal-Shamanna R; Departments of Hematopathology, and, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Chien K; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Maiti A; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kantarjian H; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Short NJ; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Am J Hematol ; 97(12): 1560-1567, 2022 12.
Article en En | MEDLINE | ID: mdl-36087091
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Subunidad alfa 2 del Factor de Unión al Sitio Principal Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Am J Hematol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Subunidad alfa 2 del Factor de Unión al Sitio Principal Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Am J Hematol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos